Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Several studies have evaluated the effect of nasal high-flow (NHF) therapy to enhance exercise performance and tolerance in patients with chronic obstructive pulmonary disease (COPD); however, results are disparate. The aim of this systematic review and meta-analysis was to assess the effect of NHF therapy as an adjuvant to exercise training on functional exercise capacity in patients with COPD. An electronic search was performed in the following databases: PubMed, the Cochrane Central Register of Controlled Trials, the Physiotherapy Evidence Database, ScienceDirect, the Web of Science, OpenGrey, ClinicalTrials.gov, and European Respiratory Society and American Thoracic Society databases. Two authors independently selected relevant randomized trials (parallel-group or crossover design), extracted data, assessed the risk of bias, and rated the quality of the evidence. Eleven studies were included, involving 408 participants (eight full papers and three conference abstracts). Most studies had a high risk of bias or other methodological limitations. The use of NHF therapy during a single session increased functional exercise capacity (standardized mean difference, 0.36 [95% confidence interval (CI), 0.03 to 0.69];  = 0.03, heterogeneity [ = 83%]). When conference abstracts were included in the pooled analysis, the estimated effect did not change ( = 0.006). The use of NHF therapy throughout a pulmonary rehabilitation program (parallel-group randomized controlled trials) increased functional exercise capacity at 4-12 weeks compared with training without NHF therapy (standardized mean difference, 0.34 [95% CI, 0.00-0.68];  = 0.05, heterogeneity [ = 18%]). There is very-low-quality to low-quality evidence that NHF therapy improves functional exercise capacity. Patient responses to NHF therapy were highly variable and heterogeneous, with benefits ranging from clinically trivial to worthwhile.

Download full-text PDF

Source
http://dx.doi.org/10.1513/AnnalsATS.202104-436SRDOI Listing

Publication Analysis

Top Keywords

nhf therapy
28
functional exercise
16
exercise capacity
16
nasal high-flow
8
therapy
8
patients chronic
8
chronic obstructive
8
obstructive pulmonary
8
pulmonary disease
8
systematic review
8

Similar Publications

Background: Routine invasive coronary angiography (ICA) is recommended for patients presenting with non-ST-segment elevation myocardial infarction (NSTEMI), but the rate of adherence to this recommendation in Australia is not known.

Aims: We sought to quantify the proportion of patients who undergo ICA and revascularization in a contemporary cohort of NSTEMI patients, and to determine predictors of clinical outcome.

Methods: This was a population-based cohort study of consecutive patients transported by emergency medical services (EMS) in Victoria, Australia with chest pain who were diagnosed with NSTEMI between January 1, 2015, and June 30, 2019.

View Article and Find Full Text PDF

Background: Repositioning existing marketed drugs represents a viable strategy for identifying new anticancer agents. This study employed an approach that combined these drugs and examined their molecular mechanisms of action against cancer.

Objective: This study evaluated the anticancer properties of the linagliptin-rivaroxaban mixture and its molecular anticancer mechanism by screening its ability to target the mutant MAPK-RAS kinase signal proteins.

View Article and Find Full Text PDF

Carbon Dot-Enhanced Doxorubicin Liposomes: A Dual-Functional Nanoplatform for Cancer Therapy.

Int J Mol Sci

August 2025

Department of Natural and Synthetic Polymers, Faculty of Chemical Engineering and Environmental Protection, "Gheorghe Asachi" Technical University of Iasi, 700050 Iasi, Romania.

Liposomes (LPs) represent one of the most effective nanoscale platforms for drug delivery in cancer therapy due to their favorable pharmacokinetic and various body tissue compatibility profiles. Building on recent findings showing that carbon dots derived from N-hydroxyphthalimide (CDs-NHF) possess intrinsic antitumor activity, herein, we investigate the possibility of preparing complex nano-platforms composed of LPs encapsulating CDs-NHF and/or doxorubicin (DOX) for breast and lung cancer. Various LP formulations were prepared and characterized using Cryo-TEM and Cryo-SEM for morphological analysis, while zeta potential and fluorescence assessments confirmed their stability and optical properties.

View Article and Find Full Text PDF

Severe bleeding episodes (BEs) in persons with hemophilia A or B and inhibitors (PwHABIs) represent challenging clinical situations and can require treatment regimens lasting days or weeks before hemostatic control is achieved. Eptacog beta is a recombinant activated human factor VII bypassing agent approved for treating and controlling bleeding in PwHABIs aged ≥12 years. The aim of this study is to assess the efficacy and safety of eptacog beta for severe bleed treatment in PwHABIs during 2 phase 3 trials (PERSEPT 1 and PERSEPT 2).

View Article and Find Full Text PDF

Nasal high flow therapy in the emergency department - A prospective study.

Int Emerg Nurs

September 2025

Mātanga Tapuhi Nurse Practitioner, Emergency and Primary Health Care, Te Moana-a-Toi Bay of Plenty, New Zealand. Electronic address:

Background: Globally, emergency department (ED) nurses routinely care for patients requiring respiratory support; this support may include nasal high flow (NHF) therapy.

Objective: The study objective was to profile and evaluate the outcomes of ED patients receiving NHF respiratory support compared to those receiving all other forms of respiratory support.

Methods: A prospective, observational, multicenter method was used to capture real-time, real-world epidemiological data at four New Zealand EDs for two 12-hour periods in April and May 2023.

View Article and Find Full Text PDF